Tomiyama, Yoshiaki
Cheze, Stèphane
Grant, Laura
Bonner, Nicola
Affinito, Sylvain
Nagano, Mitsuhiro
Rajput, Tanvi
Viana, Ricardo
Funding for this research was provided by:
Novartis
Article History
Received: 10 November 2021
Revised: 14 April 2022
Accepted: 1 May 2022
First Online: 8 June 2022
Declarations
:
: Laura Grant and Nicola Bonner were working for Adelphi Values at the time of writing the manuscript. Adelphi Values were working as consultants on behalf of Novartis. Stéphane Cheze received funding from Novartis. Yoshiaki Tomiyama has received consultancy fees and funding from Sysmex Corp, Novartis, Kyowa Kirin and Kissel Pharmaceutical co, Ltd. Mitsuhiro Nagano was the employee of Novartis when the study was conducted and is presently employed with Pfizer Japan Inc, Japan. Sylvian Affinito, Tanvi Rajput and Ricardo Viana are the employees of Novartis and contributed during the conduct of study and manuscript development. Ricardo Viana holds stocks in Novartis Pharma AG. This study is funded by Novartis Pharma AG.